Licensing status

Publication and contact information



DNA-damage-inducible transcript 4 (DDIT4; RTP801; REDD1)

Rodent and human studies suggest inhibiting REDD1 could help treat major depressive disorder (MDD). In postmortem human prefrontal cortex samples from patients with MDD, mRNA expression of the mammalian target of rapamycin complex 1 (mTORC1) inhibitor REDD1 was increased compared with that in samples from individuals without MDD. Redd1 knockout mice showed resistance to chronic stress-induced behaviors and decreases in mTORC1 signaling and the number and function of spine synapses compared with wild-type mice. In rats, injection of a REDD1-expressing viral vector into the prefrontal cortex induced behaviors and neuronal atrophy similar to those caused by chronic stress. Next steps include screening for compounds that disrupt the effect of REDD1.
Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. and Pfizer Inc. have PF-655, an siRNA targeting REDD1, in Phase II testing to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD).

SciBX 7(19); doi:10.1038/scibx.2014.564
Published online May 15, 2014

Unpatented; unavailable for licensing

Ota, K.T. et al. Nat. Med.; published online April 13, 2014;
Contact: Ronald S. Duman, Yale School of Medicine, New Haven, Conn.